Sugi Predict

Sugi Predict / Targets / CYP4F8

CYP4F8

Cytochrome P450 4F8 · P98187 · CYP4F8 on Sugi Atlas →

6,979 patent compounds predicted against CYP4F8, 4,520 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2752346 SCHEMBL2752346 0.52 3/20
SCHEMBL2752131 SCHEMBL2752131 0.52 3/20
SCHEMBL1165314 SCHEMBL1165314 0.47 3/20
SCHEMBL971260 SCHEMBL971260 0.42 3/20
SCHEMBL2749440 SCHEMBL2749440 0.42 3/20
SCHEMBL2091704 SCHEMBL2091704 0.41 3/20
SCHEMBL971261 SCHEMBL971261 0.40 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2566375) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592428) 0.90 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2570005) 0.89 2/20
SCHEMBL2584612 SCHEMBL2584612 0.79 2/20
SCHEMBL2407878 SCHEMBL2407878 0.74 2/20
SCHEMBL196765 SCHEMBL196765 0.73 2/20
SCHEMBL2580241 SCHEMBL2580241 0.72 2/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2592437) 0.70 2/20
SCHEMBL2582318 SCHEMBL2582318 0.68 2/20
SCHEMBL1180429 SCHEMBL1180429 0.67 2/20
SCHEMBL1181635 SCHEMBL1181635 0.67 2/20
SCHEMBL1181204 SCHEMBL1181204 0.65 2/20
SCHEMBL2565135 SCHEMBL2565135 0.65 2/20

Clinical trials — most relevant to CYP4F8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies PHASE4RECRUITING
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer PHASE3WITHDRAWN
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2UNKNOWN
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults PHASE2RECRUITING
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia PHASE2COMPLETED
3 Month PHI PAD PoM Study PHASE2COMPLETED
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy PHASE2RECRUITING
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis PHASE2COMPLETED
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer PHASE2WITHDRAWN
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
Study of FCN-098 in Patients With Advanced Solid Tumor PHASE1UNKNOWN
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Study of BEBT-908 in Subjects With Advanced Hematological Tumors PHASE1COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors PHASE1UNKNOWN
Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma PHASE1COMPLETED
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer PHASE1COMPLETED
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer PHASE1ACTIVE_NOT_RECRUITING
Identification of Null Allelic Variant of CYP2C8 In A Korean Population PHASE1COMPLETED
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma PHASE1COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
The Study of Warfarin Maintenance Dose in Chinese Patients nanUNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Pharmacogenetic Dosage Algorithm for Acenocoumarol nanCOMPLETED
Effects of Genotype on CYP2C9 Drug Interactions nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP4F8 binder may also engage these)

ProteinNameSimilarity
P51869 — 1.000 P51869 →
CYP4F2 Cytochrome P450 4F2 1.000 landscape →
Q9EP75 — 1.000 Q9EP75 →
CYP4F3 Cytochrome P450 4F3 0.999 landscape →
P51870 — 0.999 P51870 →
Q99N16 — 0.998 Q99N16 →
P51871 — 0.998 P51871 →
Q3MID2 — 0.996 Q3MID2 →
P33274 — 0.996 P33274 →
CYP4F12 Cytochrome P450 4F12 0.995 landscape →
Q9GLL1 — 0.994 Q9GLL1 →
Q6NT55 — 0.993 Q6NT55 →
Q9W011 — 0.992 Q9W011 →
Q5RCN6 — 0.990 Q5RCN6 →
CYP4F11 Cytochrome P450 4F11 0.989 landscape →
P15129 — 0.989 P15129 →
A2RRT9 — 0.988 A2RRT9 →
Q9VLZ7 — 0.988 Q9VLZ7 →
Q6ZWL3 — 0.988 Q6ZWL3 →
Q9VYY4 — 0.988 Q9VYY4 →
Q9DBW0 — 0.987 Q9DBW0 →
Q9VXY0 — 0.987 Q9VXY0 →
O46054 — 0.987 O46054 →
CYP4Z1 Cytochrome P450 4Z1 0.985 landscape →
CYP4X1 Cytochrome P450 4X1 0.985 landscape →
Q9VL92 — 0.984 Q9VL92 →
Q9V7G5 — 0.984 Q9V7G5 →
Q2KIG5 — 0.983 Q2KIG5 →
P82713 — 0.983 P82713 →
Q9V675 — 0.983 Q9V675 →